-
-
-
-
-
-
-
AllianceBernstein AUM rises 2% to $899 billion in May 2026
-
-
-
-
-
-
-
AllianceBernstein (AB) Misses Q1 EPS by 1c
-
-
-
-
-
-
-
AB Announces February 28, 2026 Assets Under Management
-
-
-
-
-
-
-
AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 2041
-
-
-
-
-
-
-
AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of function
-
-
-
-
-
-
-
AB Science shares initial phase 1 data for AB8939-venetoclax combination
-
-
-
-
-
-
-
AllianceBernstein reports August assets under management at $844 billion
-
1,205,326 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

